Selective amplification of rare mutations using locked nucleic acid oligonucleotides that competitively inhibit primer binding to wild-type DNA

Journal of Investigative Dermatology

Volumn 128, Issue 2, 2008, Pages 398-402

  Oldenburg, Reid P ^a   Liu, Monica S ^a   Kolodney, Michael S ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GENOMIC DNA; LOCKED NUCLEIC ACID; OLIGONUCLEOTIDE;

ARTICLE; CANCER STAGING; DNA BINDING; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; POINT MUTATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WILD TYPE;

EID: 38149000163     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5700920     Document Type: Article

References (13)

1. Collison E, De A, Suzuki H, Gambhir SS, Kolodney MS (2003) Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf - MAPK cascade. Cancer Res 63:5669-73
2. Cohen Y, Goldenberg N, Parrella P, Chowers I, Merbs S, Pe'er J et al. (2003) Lack of BRAF mutation in primary uveal melanoma. Invest Ophth Vis Sci 44:625-7
3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-54
4. Dominguez PL, Kolodney MS (2005) Wild-type blocking polymerase chain reaction. Oncogene 24:6830-4
5. Hosono S, Faruqi AF, Dean FB, Du Y, Sun Z, Wu X et al. (2003) Unbiased whole-genome amplification directly from clinical samples. Genome Res 13:954
6. Jarry A, Masson D, Cassagnau E, Parois S, Laboisse C, Denis M (2004) Realtime allele specific amplification for sensitive detection of the BRAF mutation V600E. Mol Cell Probes 18:349-52
7. Keilholz U, Willhauck M, Rimoldi D, Brasseur F, Dummer W, Rass K et al. (1998) Reliability of reverse transcription-polymerase chain reaction (RTPCR)-based assays for the detection of circulating tumor cells: a quality-assurance initiative of the EORTC Melanoma Cooperative Group. Eur J Cancer 34:750-3
8. Koyanagi K, Kuo C, Nakagawa T, Mori T, Ueno H, Lorico A et al. (2005) Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem 51:981-8
9. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhonen S et al. (2003) BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 9:3362-8
10. Lansdorp PM, Thomas TE (1990) Purification and analysis of bispecific tetrameric antibody complexes. Mol Immunol 27:659
11. Pantel K, Doeberitz M (2000) Detection and clinical relevance of micrometastatic cancer cells. Oncology 12:95-101
12. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358-62
13. Ulmer A, Schmidt-Kittler O, Fischer J, Ellwanger U, Rassner G, Riethmuller G et al. (2004) Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. Clin Cancer Res 10:531-7